Skip to content
Review

RTS,S/AS01 mRNA Booster Platforms for Sustaining Protective Immunity Against Plasmodium Falciparum in African Children

Sep 2026 · IDOSR JOURNAL OF EXPERIMENTAL SCIENCES · 0 citations

Abstract

Malaria caused by Plasmodium falciparum remained a leading cause of morbidity and mortality among African children, with hundreds of thousands of paediatric deaths annually despite expanded control measures. The RTS,S/AS01 pre-erythrocytic vaccine had demonstrated moderate efficacy, reducing clinical malaria episodes by approximately 45–50% in children aged 5–17 months, but protection wanes over time and is substantially lower in young infants, underscoring the need for strategies that sustain and amplify vaccine-induced immunity. This narrative review exploreed emerging concepts around RTS,S/AS01 mRNA booster platforms as a means to prolong protective immunity against P. falciparum in African children, integrating current evidence on RTS,S/AS01 performance, mRNA vaccine immunobiology, and booster strategies in high-transmission settings. A narrative review methodology was employed, drawing from randomized trials, implementation studies, and mRNA vaccine literature indexed in major databases up to mid-2026. Findings from phase 3 trials revealed that RTS,S/AS01 efficacy is enhanced by a fourth booster dose and by seasonal schedules combined with chemoprevention, but long-term protection remains incomplete. Parallel advances in mRNA technology suggested that mRNA-encoded circumsporozoite antigen boosters could re-engage B and T cell memory more flexibly and repeatedly, potentially overcoming waning immunity while enabling rapid adaptation to parasite antigenic variation. RTS,S/AS01 mRNA booster platforms represented a promising, though still theoretical, avenue for sustaining protective immunity against P. falciparum in African children, contingent on solving challenges of cost, cold-chain logistics, and equitable access. Keywords: RTS,S/AS01, Malaria vaccine, mRNA booster, Plasmodium falciparum, African children.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.